Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
An expert discusses how molecular profiling has become essential for most solid tumor cancers, particularly in lung cancer, where both tissue- and plasma-based testing using next-generation sequencing help identify actionable genomic targets and monitor resistance patterns.
EP: 1.Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
EP: 2.Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
EP: 3.Clinical Impact and Perspectives on Comprehensive Genomic Profiling in Advanced Lung Cancer Management
EP: 4.Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
EP: 5.What’s Next for Comprehensive Genomic Profiling in Cancer Care
EP: 6.Employing Comprehensive Genomic Testing in the NSCLC Paradigm
Video content above is prompted by the following:
The National Comprehensive Cancer Network (NCCN) provides specific recommendations for comprehensive genomic profiling in metastatic non–small cell lung cancer management. These guidelines address the strategic use of plasma testing in relation to tissue samples, outlining pros and cons of each approach. The recommendations emphasize when plasma testing may require reflexive tissue testing, particularly in cases of low tumor fraction where insufficient DNA in plasma necessitates tissue-based analysis to prevent missed results.
Hatim Husain, MD, observes increasing guideline adherence in community practice settings, noting improvements in meeting previously unmet needs for broader testing adoption. However, opportunities for improvement remain, particularly in developing appropriate workflows and educational initiatives. The focus on streamlining clinic flow and completing testing processes requires targeted education about each genomic target’s relevance and practical implementation strategies.
Successful implementation of comprehensive genomic profiling requires systematic workflow optimization and multidisciplinary team coordination. This includes establishing efficient processes for test ordering, result reporting, and clinical decision-making based on molecular findings. The integration of genomic testing into routine clinical practice demands ongoing education and process refinement to ensure timely, comprehensive molecular characterization of advanced lung cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
